When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

The efficacy and safety of risankizumab remains similar across racial and ethnic groups of patients with moderate to severe plaque psoriasis.

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

"The results from this study are aligned with our commitment to elevate the standard of care for the millions of adults impacted by moderate to severe plaque psoriasis, many of whom are currently ...

Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of ...

"The results from this study are aligned with our commitment to elevate the standard of care for the millions of adults impacted by moderate-to-severe plaque psoriasis, many of whom are currently ...

Tremfya is approved for the treatment of adults with moderate to severe plaque psoriasis who may benefit from systemic therapy or phototherapy. Johnson & Johnson NewsMORE Related Stocks Indices ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...